Trevor N. Tankersley

Trevor N. Tankersley

Auto-generated profile, based on publicly available information

Trevor N. Tankersley

Center for Immunology, University of Minnesota Medical School, Minneapolis, USA

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 January 2024 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
CBChristine M. Bradshaw
Christine M. Bradshaw
TGTeodora Georgieva
Teodora Georgieva
TTTrevor N. Tankersley
Trevor N. Tankersley
TTTama Taylor-Doyle
Tama Taylor-Doyle
LJLarry Johnson
Larry Johnson
JNJanko Nikolich-Žugich
Janko Nikolich-Žugich
A popular mouse model of COVID-19, the K18-hACE2 mouse, expresses the SARS-coronavirus entry receptor, human angiotensin-converting enzyme 2 (hACE2) driven by the keratin-18 promoter. SARS-CoV-2–infected K18-hACE2 mice exhibit neuropathology not representative of human infection. They contain eight transgene (Tg) copies, leading to excess hACE2 expression and rampant viral replication. We generated two new lines of K18-hACE2 mice encoding one and two copies of hACE2 (1-hACE2-Tg and 2-hACE2-Tg, respectively). Relative to the original strain (called 8-hACE2-Tg in this study), 2-hACE2-Tg mice exhibited lower mortality, with less viral replication in the lung and brain. Furthermore, 1-hACE2-Tg mice exhibited no mortality and had no detectable virus in the brain; yet, they exhibited clear viral replication in the lung. All three strains showed SARS-CoV-2–related weight loss commensurate with the mortality rates. 1-hACE2-Tg mice mounted detectable primary and memory T effector cell and Ab responses. We conclude that these strains provide improved models to study hACE2-mediated viral infections.

10 February 2026 in Nature Immunology
Verified
Journal Article
Closed access
PDF file
NMNicholas J. Maurice
Nicholas J. Maurice
TDTalia S. Dalzell
Talia S. Dalzell
TTTrevor N. Tankersley
Trevor N. Tankersley
KRKa Hyun Rhee
Ka Hyun Rhee
KBKatharine E. Block
Katharine E. Block
SJStephen C. Jameson
Stephen C. Jameson

2 November 2026 in The Journal of Immunology
Verified
Journal Article
Open access
JHJacob A Hildebrand
Jacob A Hildebrand
ELErin D Lucas
Erin D Lucas
NDNoah R Daniels
Noah R Daniels
BFBenjamin D Fisher
Benjamin D Fisher
CJChris J Janse
Chris J Janse
SHSara E Hamilton
Sara E Hamilton
Cerebral malaria (CM) is a life-threatening complication of Plasmodium infection driven in part by an overwhelming inflammatory response. No clinical therapies are approved that specifically prevent immunopathology during CM. In experimental cerebral malaria (ECM), vascular endothelial cells in the mouse brain cross-present malaria antigen and upregulate adhesion molecules in response to inflammation. This causes CD8 T-cell arrest, activation, and lethal disruption of the blood-brain barrier. We previously reported that treatment with IL-15 cytokine complex (IL-15C) prevents ECM by inducing natural killer (NK) cell secretion of IL-10. To further uncover the mechanisms underlying this immunotherapy, OT-I T cells were transferred into mice, followed by infection with ovalbumin-expressing Plasmodium berghei. Using intravital microscopy, we observed major areas of OT-I arrest within the brains of untreated mice experiencing ECM. IL-15C treatment reduced the number of arresting OT-I T cells, coinciding with an increased mean velocity when compared to untreated mice. To identify the target of NK cell–secreted IL-10, we used conditional knockouts of IL-10Rα and found that protection from ECM occurs through IL-10Rα on endothelial cells and not CD8 T cells. Coinciding with this, IL-15C reduced the expression of adhesion molecules, selectins, and MHC-I on brain endothelial cells. In summary, our studies support the mechanism that IL-15C treatment reduces the number of arrested CD8 T cells along the cerebral vasculature by modulating endothelial cells to prevent ECM. These insights demonstrate the potential for treatments that reduce T-cell arrest to improve outcomes of human CM.

1 September 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
CBChristine M. Bradshaw
Christine M. Bradshaw
TGTeodora Georgieva
Teodora Georgieva
TTTrevor N. Tankersley
Trevor N. Tankersley
TTTama Taylor-Doyle
Tama Taylor-Doyle
LJLarry Johnson
Larry Johnson
JNJanko Nikolich-Žugich
Janko Nikolich-Žugich
Coronaviridae are significant human pathogens, as evidenced by several outbreaks of severe respiratory infections in the past 20 years and culminating with the COVID-19 pandemic. Mouse models of COVID-19 have included transgenic expression of the main SARS coronavirus entry receptor on human cells, human angiotensin-converting enzyme 2 (hACE2). However, the original hACE2-Tg mouse strain overexpresses many copies of the transgene, leading to neuropathology not representative of human infection. Aiming to improve physiological relevance, we generated two new lines of hACE2-Tg mice using the original transgene construct expressing hACE2 under the control of the keratin 18 promoter (K18-hACE2). We show that relative to the original strain, which expressed 8 copies of the transgene (8-hACE2-Tg), lines 1 and 2 expressed 1 and 2 copies of the transgene (1-hACE-2-Tg and 2-hACE-2-Tg, respectively). Upon intranasal (i.n.) infection with 10 3 plaque-forming units (pfu) SARS-CoV-2 WA-1/US, 8-hACE2-Tg mice succumbed to infection by d. 7. 2-hACE2-Tg mice exhibited 31% survival, with less viral replication in the lung and brain when compared to 8-hACE2-Tg mice. Furthermore, SARS-CoV-2 infection in 1-hACE2-Tg mice exhibited no mortality and had no detectable virus in the brain, although they did show clear virus replication in the lung. All three mouse strains analyzed showed SARS-CoV-2-related weight loss that tracked with the mortality rates. 1-hACE2-Tg mice mounted detectable primary and memory T effector cell and antibody responses. We conclude that these strains, particularly 1-hACE2-Tg mice, provide improved models to study hACE2-mediated viral infections.